Equities research analysts predict that VIVUS, Inc. (NASDAQ:VVUS) will announce earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for VIVUS’s earnings. VIVUS reported earnings per share of $0.54 in the same quarter last year, which suggests a negative year-over-year growth rate of 124.1%. The business is expected to announce its next quarterly earnings report on Wednesday, March 14th.
On average, analysts expect that VIVUS will report full year earnings of ($0.32) per share for the current year. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for VIVUS.
VIVUS (NASDAQ:VVUS) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.07. The company had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. VIVUS’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.09) EPS.
Institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in shares of VIVUS by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 114,564 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 7,722 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of VIVUS by 84.8% in the second quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 68,200 shares in the last quarter. Creative Planning lifted its holdings in shares of VIVUS by 1,691.3% in the fourth quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 346,235 shares in the last quarter. Macquarie Group Ltd. bought a new position in shares of VIVUS in the third quarter valued at approximately $192,000. Finally, Northern Trust Corp lifted its holdings in shares of VIVUS by 16.8% in the second quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock valued at $335,000 after purchasing an additional 39,473 shares in the last quarter. Institutional investors own 31.33% of the company’s stock.
Shares of VIVUS (NASDAQ VVUS) remained flat at $$0.47 during mid-day trading on Monday. The company’s stock had a trading volume of 452,100 shares, compared to its average volume of 513,546. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86. The firm has a market capitalization of $50.33, a P/E ratio of 1.38 and a beta of 0.80. VIVUS has a twelve month low of $0.45 and a twelve month high of $1.38.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) to Announce -$0.13 EPS” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/22/zacks-analysts-anticipate-vivus-inc-vvus-to-announce-0-13-eps.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.